Some Pediatric Patients With Wilms' Tumor Can Avoid Doxorubicin
the ONA take:
According to a new study published in the journal The Lancet, researchers have found that children with Wilm's tumor who are at low risk for relapse can be given less intensive treatment by omitting doxorubicin from the treatment regimen.
For the 10-year trial, researchers followed 583 pediatric patients with stage II or III Wilm's tumor who were at intermediate risk for disease relapse. Results demonstrated that 96.5% of patients whose treatment regimen contained doxorubicin survived for 5 or more years versus 95.8% of those who did not receive the cardiotoxic drug. Researchers found that those who did not receive doxorubicin and relapsed could be successfully re-treated.
"Thanks to the results of this trial fewer children with this disease will have to have treatment that could cause them lifelong side effects without much benefit," lead author Professor Kathy Pritchard-Jones, a researcher at the Institute of Child Health, University College London and consultant oncologist at Great Ormond Street Hospital in London said.
Children with Wilm's tumor who are at low risk for relapse can be given less intensive treatment by omitting doxorubicin from the treatment regimen.
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- Atezolizumab Granted FDA Approval for Specific Cases of NSCLC
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- HIIT Improves Cardiorespiratory Fitness in Patients With Resectable NSCLC
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Recurrence Score Appears To Be Driving Personalized Treatment for Breast Cancer
- Smoking-related Cancer Deaths Highest in Southern United States
- Study Suggests More Men With Prostate Cancer Would Choose Active Surveillance if it Were Offered
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|